Current therapy of shock.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001314:Auscultation; D002301:Cardiac Glycosides / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006439:Hemodynamics; D006801:Humans; D008616:Mephentermine / Q000627:therapeutic use; D008729:Methoxamine / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D011674:Pulse; D012769:Shock / Q000503:physiopathology / Q000628:therapy*; D012771:Shock, Hemorrhagic / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D012772:Shock, Septic / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy
D000317:Adrenergic alpha-Antagonists; D002301:Cardiac Glycosides; D005934:Glucagon; D008729:Methoxamine; D008616:Mephentermine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine